Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Inclusion Criteria

• •Outpatient at least 12 years of age
• •Both genders; females of childbearing potential must be willing to use birth control method
• •Clinical diagnosis of asthma for ≥12 weeks
• •Best pre-bronchodilator FEV1 of 40%-90% predicted
• •Reversibility of FEV1 of at least 12% and 200mls
• •Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks prior to 1st visit
• •Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits